Zacks Investment Research on MSN6d
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharmaBayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback